Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...2122232425262728293031...401402»
  • ||||||||||  Journal:  Identification of Osteosarcopenia by High-Resolution Peripheral Quantitative Computed Tomography. (Pubmed Central) -  Sep 29, 2024   
    These findings demonstrated that HR-pQCT is a viable and effective screening method for differentiating osteosarcopenia from low bone mineral density alone without the need to carry out multiple assessments for osteosarcopenia, especially for case-finding purposes. This could facilitate the decision of a follow-up and the management of these frail older adults to ensure they receive timely therapeutic interventions to minimise the associated risks.
  • ||||||||||  Review, Journal:  Does Vitamin B6 Act as an Exercise Mimetic in Skeletal Muscle? (Pubmed Central) -  Sep 29, 2024   
    Here, we provide several pieces of evidence supporting this hypothesis and discuss the potential mechanisms behind the similarities between the effects of B6 and exercise on muscle. This research, for the first time, provides insight into the exercise-mimetic roles of B6 in skeletal muscle.
  • ||||||||||  Review, Journal:  Vascular Impairment, Muscle Atrophy, and Cognitive Decline: Critical Age-Related Conditions. (Pubmed Central) -  Sep 29, 2024   
    This study emphasizes the complex interplay between vascular dysfunction, muscle degeneration, and cognitive decline, highlighting the necessity for multidisciplinary treatment approaches. Advances in this domain promise improved diagnostic accuracy, more effective therapeutic options, and enhanced preventive measures, all contributing to a higher quality of life for the elderly population.
  • ||||||||||  Review, Journal:  Cellular Senescence: The Driving Force of Musculoskeletal Diseases. (Pubmed Central) -  Sep 29, 2024   
    Undoubtedly, targeting senescent cells and their secretory profiles could promote the development of integrated strategies, including regular exercise and a balanced diet or the use of senolytics and senomorphs, to improve the quality of life of the aging population. Therefore, our review aimed to highlight the role of cellular senescence in age-related musculoskeletal diseases, summarizing the main underlying mechanisms and potential anti-senescence strategies for the treatment of osteoporosis, sarcopenia, and osteoarthritis.
  • ||||||||||  Development of a Deep Learning Model for Automated Measurement of Skeletal Muscle Mass in [18F]F-FDG PET/ CT Scans (Hall Y10-Y12) -  Sep 27, 2024 - Abstract #EANM2024EANM_1411;    
    The study demonstrated that our 3D segmentation deep learning model could reasonably measure skeletal muscle mass from whole-body CT images in PET/CT scans. PET/CT is expected to become an increasingly important tool for personalized medicine, as it can acquire not only tumor accumulation values (SUVmax) from PET images, but also non-tumor parameters such as muscle mass that reflect individual patient characteristics from CT images.
  • ||||||||||  PET/CT radiomics combined with clinical features in predicting sarcopenia and prognosis of diffuse large B-cell lymphoma (Hall Y4-Y9) -  Sep 27, 2024 - Abstract #EANM2024EANM_997;    
    PET/CT is expected to become an increasingly important tool for personalized medicine, as it can acquire not only tumor accumulation values (SUVmax) from PET images, but also non-tumor parameters such as muscle mass that reflect individual patient characteristics from CT images. ML models incorporating clinical and PET/CT radiomics features could effectively predict the presence of sarcopenia and assess the prognosis in patients with DLBCL.
  • ||||||||||  Journal:  Countermovement Jump Peak Power Changes with Age in Masters Weightlifters. (Pubmed Central) -  Sep 27, 2024   
    Female weightlifters exhibited less age-related decline compared to normative data as well as the other Master athlete comparison cohorts (short and long-distance runners), whereas the males demonstrated similar age-related declines as the comparison cohorts. While the female weightlifters in the current study generally demonstrated the least age-related declines in CMJ peak power of the comparative literature, the male weightlifters showed similar age-related decline rates.
  • ||||||||||  Journal:  Dietary selenium intake and sarcopenia in American adults. (Pubmed Central) -  Sep 27, 2024   
    Furthermore, sensitivity analyses revealed a robust association between selenium intake and the prevalence of sarcopenia after further adjusting for blood selenium levels. The results suggest an inverse association between dietary selenium intake and the prevalence of sarcopenia among American adults.
  • ||||||||||  Preclinical, Journal:  Chronic whole-body heat treatment in obese insulin-resistant C57BL/6J mice. (Pubmed Central) -  Sep 26, 2024   
    It also lowered the H-index of HSP70 balance, indicating improved immunoinflammatory status, and decreased activated caspase-1 and proliferative senescence in adipose tissue, both linked to insulin resistance. The findings suggest that even animals on a "control" diet but with insufficient physical activity and within their TNZ may experience impaired glycaemic homeostasis.
  • ||||||||||  Trial completion date, Trial primary completion date:  Evaluation of Sarcopenia in Patients Receiving Home Health Care (clinicaltrials.gov) -  Sep 26, 2024   
    P=N/A,  N=120, Recruiting, 
    The findings suggest that even animals on a "control" diet but with insufficient physical activity and within their TNZ may experience impaired glycaemic homeostasis. Trial completion date: Feb 2024 --> Oct 2024 | Trial primary completion date: Feb 2024 --> Oct 2024
  • ||||||||||  Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Abdominal Skeletal Muscle Compartments in Turkish Children (clinicaltrials.gov) -  Sep 25, 2024   
    P=N/A,  N=2300, Active, not recruiting, 
    Trial completion date: Feb 2024 --> Oct 2024 | Trial primary completion date: Feb 2024 --> Oct 2024 Not yet recruiting --> Active, not recruiting | N=5000 --> 2300 | Trial completion date: Mar 2024 --> Oct 2024 | Trial primary completion date: Mar 2024 --> Oct 2024
  • ||||||||||  Review, Journal:  MicroRNAs and their Modulatory Effect on the Hallmarks of Osteosarcopenia. (Pubmed Central) -  Sep 24, 2024   
    activity, presenting it as a target for developing analogues that restore its function. Finally, microRNA-672 stands out for its ability to protect skeletal muscle and bone when expressed in the disease, highlighting its potential as a possible therapy for osteosarcopenia.